GLTO Overview

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for cancer and liver diseases. The Company’s pipeline consists of small molecule drug candidates that target cancer and fibrosis signaling pathways, including a preclinical dual inhibitor of ENL-YEATS and FLT3 (GB3226) for multiple genetic subsets of AML; an orally active galectin-3 inhibitor (GB1211) in combination with a checkpoint inhibitor for various oncology indications and (an orally active galectin-3 inhibitor (GB1211) for the treatment of liver cirrhosis. It is developing GB3226, a preclinical small molecule dual inhibitor of ENL-YEATS and FLT3 for multiple molecularly defined subsets of acute myeloid leukemia (AML). The Company’s pipeline is GB1211, its oral small molecule galectin-3 inhibitor candidate, which is in development for the treatment of non-small cell lung cancer (NSCLC), melanoma, head and neck squamous cell carcinoma (HNSCC), and decompensated cirrhosis.

Wall Street analysts forecast GLTO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLTO is41.00 USD with a low forecast of 36.00 USD and a high forecast of 46.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Galecto Inc revenue for the last quarter amounts to -3.00M USD, decreased -17.81 % YoY.

Galecto Inc. EPS for the last quarter amounts to -2616000.00 USD, decreased -28.35 % YoY.

Galecto Inc (GLTO) has 5 emplpoyees as of January 29 2026.

Today GLTO has the market capitalization of 39.00M USD.